Literature DB >> 33353400

Lung cancer screening with low-dose computed tomography at a tertiary hospital in Anhui, China and secondary analysis of trial data.

Wulin Shan1, Zhaowu Chen1, Donghua Wei1, Ming Li1, Liting Qian1.   

Abstract

OBJECTIVE: Lung cancer screening with low-dose computed tomography (LDCT) partly reduces cancer-specific mortality. However, few data have described this specific population for screening in mainland China. Here, we conducted a population-based screening program in Anhui, China.
METHODS: 9084 individuals were participating in the screening program for lung cancer in Anhui province from 1 June 2014 to 31 May 2017. LDCT was offered to all participants who joined the program.
RESULTS: Of 9084 individuals undergoing LDCT, we detected 54 lung cancers (0.594%). The age with the highest rate was 61-65 years (up to 1.016%), followed by 56-60 (0.784%). Most patients (98.1%, 53/54) were in stage I-II (early stage), and only one was in stage III (advanced stage). Adenocarcinoma, squamous cell carcinoma and small cell lung cancer accounted for 57.4% (31/54), 37% (20/54) and 5.6% (3/54) of the individuals, respectively. Notably, There were 4,102 never smokers in our study. The median age was 63 years. Males and females accounted for 53.4 and 46.6%, respectively. Among the 4102 never smokers, 96 participants had a positive family cancer history. Additionally, we detected 20 lung cancers (0.488%), slightly lower than the whole rate 0.594%. Finally, our data showed that age, smoking, family cancer history and features of nodules were risk factors for lung cancer.
CONCLUSION: Our study qualified the efficiency of LDCT to detect early-stage lung cancers in Anhui, China. Further establishment of appropriate lung cancer screening methods specifically for individuals in China is warranted. ADVANCES IN KNOWLEDGE: We evaluated the performance of lung cancer screening for asymptomatic populations using LDCT in Anhui, an eastern inland province of China. Our study qualified the efficiency of LDCT to detect early-stage lung cancers in Anhui, China.

Entities:  

Mesh:

Year:  2020        PMID: 33353400      PMCID: PMC7934288          DOI: 10.1259/bjr.20200438

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  16 in total

Review 1.  [Systematic review of the relationship between family history of lung cancer and lung cancer risk].

Authors:  Jundong Gu; Feng Hua; Diansheng Zhong; Jun Chen; Hongyu Liu; Qinghua Zhou
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-03

Review 2.  CT screening for lung cancer: Is the evidence strong enough?

Authors:  J K Field; A Devaraj; S W Duffy; D R Baldwin
Journal:  Lung Cancer       Date:  2015-11-30       Impact factor: 5.705

3.  Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer.

Authors:  E F Patz; S Rossi; D H Harpole; J E Herndon; P C Goodman
Journal:  Chest       Date:  2000-06       Impact factor: 9.410

4.  Lung Cancer Screening with Low-Dose CT: Baseline Screening Results in Shanghai.

Authors:  Li Fan; Yun Wang; Ying Zhou; Qiong Li; Wenjie Yang; Shengping Wang; Fei Shan; Xingwei Zhang; Jingyun Shi; Wufei Chen; Shi-Yuan Liu
Journal:  Acad Radiol       Date:  2018-12-14       Impact factor: 3.173

5.  Lung cancer screening with low-dose computed tomography: Experiences from a tertiary hospital in Taiwan.

Authors:  Chih-Yu Chen; Chia-Hung Chen; Te-Chun Shen; Wen-Chien Cheng; Cheng-Nan Hsu; Chun-Han Liao; Chih-Yi Chen; Te-Chun Hsia; Wei-Chih Liao; Chih-Yen Tu; Chuen-Ming Shih; Wu-Huei Hsu
Journal:  J Formos Med Assoc       Date:  2015-12-20       Impact factor: 3.282

6.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

Review 7.  Lung cancer screening: latest developments and unanswered questions.

Authors:  Carlijn M van der Aalst; Kevin Ten Haaf; Harry J de Koning
Journal:  Lancet Respir Med       Date:  2016-09       Impact factor: 30.700

8.  Lung cancer and prognosis in taiwan: a population-based cancer registry.

Authors:  Bing-Yen Wang; Jing-Yang Huang; Ching-Yuan Cheng; Ching-Hsiung Lin; Jiunn- Liang Ko; Yung-Po Liaw
Journal:  J Thorac Oncol       Date:  2013-09       Impact factor: 15.609

9.  UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer.

Authors:  D R Baldwin; S W Duffy; N J Wald; R Page; D M Hansell; J K Field
Journal:  Thorax       Date:  2011-02-11       Impact factor: 9.139

10.  Is an analytical dose engine sufficient for intensity modulated proton therapy in lung cancer?

Authors:  Suliana Teoh; Francesca Fiorini; Ben George; Katherine A Vallis; Frank Van den Heuvel
Journal:  Br J Radiol       Date:  2019-11-20       Impact factor: 3.629

View more
  1 in total

1.  Lung cancer screening with low-dose computed tomography: National expenditures and cost-effectiveness.

Authors:  Xiaohui Zeng; Zhen Zhou; Xia Luo; Qiao Liu
Journal:  Front Public Health       Date:  2022-09-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.